CONNETICS REPORTS RESULTS OF DESILUX TRIAL

Connetics announced the positive outcome of its Phase III clinical trial evaluating Desilux (desonide) VersaFoam-EF, a low-potency topical steroid formulated in the company's proprietary emollient foam delivery vehicle to treat atopic dermatitis.

The Phase III trial included 581 patients from age three months to 17 years and was designed to demonstrate superiority of Desilux over placebo foam. In the randomized and blinded study, subjects received either Desilux or placebo foam twice daily for four weeks, followed by three weeks of follow up.

The proportion of patients achieving treatment success on the primary endpoint was 39 percent for Desilux and 9 percent for placebo foam. Treatment success for a given subject was defined as clear or almost clear based on ISGA with a minimum of two-grade improvement in ISGA score from baseline, and absent or minimal erythema and induration/papulation. The data from the trial also demonstrated that Desilux was safe and well tolerated, with the most frequently observed side effects mild in nature and largely limited to application site reactions.